Developer docs
API playgroundTry for free, no card

Search company profiles

Prelude

Full company profile

uuid00024z2

Namestring
Prelude
Legal namestring
Prelude Corporation
Websiteurl
preludedx.com
Company typeenum
Private
Founded yearint
2009
Short descriptiontext

PreludeDx is a Laguna Hills-based molecular diagnostics company that develops AI-enabled multi-omic biosignature tests — DCISionRT and AidaBreast — to predict breast cancer recurrence risk and personalize radiation therapy decisions for women with early-stage disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLaguna Hills, United States
HQ citystring
Laguna Hills
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, breast cancer testing, precision oncology, genomic biosignature, radiation therapy decisions
Industry4 codes
PRIMARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Laboratory Diagnostic Testing Services
TypeOne Time License
Description

PreludeDx operates as a CLIA-certified laboratory offering molecular diagnostic tests (DCISionRT and AidaBreast) to healthcare providers and patients. Revenue is generated through test fees billed to insurance payers and patients. The company accepts all insurance plans and offers financial assistance programs.

preludedx.com
2Test Commercialization
TypeOne Time License
Description

Commercialization of diagnostic tests for early-stage breast cancer. Projected revenue of $40M for current year following FDA breakthrough device designation for AidaBREAST test.

ocbj.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Insurance and self-pay options available
ModelOtherBilling cadencePay-as-you-go
Notes

PreludeDx accepts all insurance plans. Patient responsibility may include deductible, co-insurance, or co-pay depending on individual plan. Financial assistance programs available for eligible patients.

GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1DCISionRT
Description

Genomic test for ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit and recurrence risk

preludedx.com
+2 more records
Core offering1 text field

PreludeDx operates a CLIA-certified molecular diagnostics laboratory that provides proprietary genomic and multi-omic biosignature tests for early-stage breast cancer. Its core products—DCISionRT for ductal carcinoma in situ (DCIS) and AidaBreast for early-stage invasive breast cancer—use AI-integrated biomarker analysis of patient tissue samples to generate Decision Scores that predict 10-year recurrence risk and identify which patients will benefit from radiation therapy. Tests are physician-ordered and results are returned within 3-5 days to support personalized treatment planning.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • DCISionRT testing changed radiation therapy recommendation in 38% of patients (n=770, p<0.0001) in PREDICT study of 2,007 patients
+4 more records
Product overview1 text field

PreludeDx (Prelude Corporation) is a molecular diagnostics company specializing in precision medicine for early-stage breast cancer. The company's portfolio consists of two core genomic tests: DCISionRT (launched 2017) for ductal carcinoma in situ (DCIS) patients, and AidaBreast (in development) for early-stage invasive breast cancer patients. Both tests use proprietary multi-omic biosignatures combined with AI algorithms to generate Decision Scores predicting recurrence risk and radiation therapy benefit. DCISionRT is a 7-gene biosignature while AidaBreast integrates spatial biology with multiplex protein expression and targeted RNA sequencing. The company also offers a web-based ordering portal and a second opinion service (Breast SOS).

Product and service3 records
1DCISionRT
CategoryMolecular Diagnostic Test
Description

A 7-gene genomic biosignature test for ductal carcinoma in situ (DCIS) that predicts 10-year recurrence risk and identifies which patients will benefit from radiation therapy following breast-conserving surgery. The test generates a Decision Score (0-10) and classifies patients as Low Risk, Elevated Risk, or Residual Risk. It is intended for breast cancer physicians (surgeons, radiation oncologists) treating DCIS patients and results are returned within 3-5 days.

2AidaBreast
CategoryMolecular Diagnostic Test
Description

A multi-omic diagnostic assay for early-stage invasive breast cancer that integrates spatial biology (multiplex immunofluorescence), targeted RNA sequencing, and AI to predict 10-year locoregional recurrence risk and radiation therapy benefit for women following breast-conserving surgery. Targets HR+/HER2-negative early-stage invasive breast cancer patients (T1-T2, node-negative) and generates a Decision Score and Radio Resistance Index (RRI).

3Breast SOS (Second Opinion Service)
CategoryClinical Decision Support Service
Description

A second opinion service offering for patients seeking additional consultation on DCIS diagnosis and treatment decisions, supporting personalized treatment planning through expert clinical review.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-04-17
Description

Quanterix and PreludeDx co-developed and validated AidaBREAST, a multi-omic assay that predicts locoregional recurrence risk and radiation therapy benefit. Quanterix's Simoa/spatial proteomics technology was integrated with RNA sequencing and AI for the assay. The assay was validated with 922 patients across US and Sweden.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

GenesisCare partnership provides global access to DCISionRT for patients, particularly through radiation oncology centers in Australia and internationally. Enables PreludeDx to expand geographically through GenesisCare's network of cancer treatment facilities.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Royal Melbourne Hospital in Australia conducted the first independent validation of AidaBreast test involving over 400 women with early-stage invasive breast cancer. The validation confirmed the test's prognostic and predictive capabilities for radiation therapy decision-making.

Strategic tierCoreTypeTechnology or Integration
Description

PreludeDx licensed biomarkers and technology from UCSF for development of DCISionRT and other breast cancer diagnostic tests. Both DCISionRT and AidaBreast tests were developed from biomarkers licensed from UCSF.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Acquired Genomic Health and Oncotype DX, the dominant 21-gene breast cancer recurrence test, making it the most direct competitor to DCISionRT in early-stage breast cancer risk stratification and treatment decision-making.

TypeDirect peer
Description

Developer of MammaPrint (70-gene signature) and BluePrint for early-stage breast cancer recurrence and molecular subtyping; directly competes with DCISionRT and AidaBreast in guiding adjuvant and radiation therapy decisions.

TypeDirect peer
Description

Markets Prosigna (PAM50) gene expression assay for breast cancer prognosis using the nCounter platform; offers an alternative genomic risk-stratification solution for postmenopausal early-stage breast cancer patients.

TypeBroad incumbent
Description

Established molecular diagnostics company offering EndoPredict for breast cancer recurrence risk as well as hereditary cancer tests (BRACAnalysis); competes across multiple precision oncology segments.

TypeDirect peer
Description

Develops Breast Cancer Index (BCI), a gene expression test predicting recurrence risk and benefit of extended endocrine therapy in early-stage HR+ breast cancer; positioned similarly to AidaBreast.

TypeBroad incumbent
Description

Genomic diagnostics company with a growing breast cancer franchise (e.g., Prosigna acquired via NanoString partnership) and broader oncology/urology test menu; competes for payer mindshare and physician adoption.

TypeBroad incumbent
Description

Specialized oncology reference laboratory offering comprehensive profiling and breast cancer assays; an alternative CLIA lab channel for hospitals ordering recurrence-risk testing.

TypeEmerging player
Description

Molecular diagnostics company expanding from cell-free DNA / MRD into oncology; a potential competitor for the multi-omic, AI-driven oncology testing market Prelude is targeting.

TypeEmerging player
Description

Offers multi-omic tumor profiling (MI Profile) combining WES/WTS, proteomics, and AI; competes for the same physician customers seeking AI-driven precision oncology decision support.

TypeBroad incumbent
Description

Liquid biopsy and precision oncology company expanding into MRD and therapy selection; adjacent competitor as blood-based alternatives emerge for early-stage breast cancer risk stratification.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prelude

Molecular Diagnosticspreludedx.com

PreludeDx is a Laguna Hills-based molecular diagnostics company that develops AI-enabled multi-omic biosignature tests — DCISionRT and AidaBreast — to predict breast cancer recurrence risk and personalize radiation therapy decisions for women with early-stage disease.

Prelude firmographics

Firmographics
Name
Prelude
Legal name
Prelude Corporation
Website
https://preludedx.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
51–100 employees
Short description
PreludeDx is a Laguna Hills-based molecular diagnostics company that develops AI-enabled multi-omic biosignature tests — DCISionRT and AidaBreast — to predict breast cancer recurrence risk and personalize radiation therapy decisions for women with early-stage disease.
Ownership category
akta.pro rank

Prelude industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Molecular diagnostics
  • Breast cancer testing
  • Precision oncology
  • Genomic biosignature
  • Radiation therapy decisions

Where Prelude is headquartered

Location

Headquarters

HQ city
Laguna Hills
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Prelude business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Laboratory Diagnostic Testing Services: PreludeDx operates as a CLIA-certified laboratory offering molecular diagnostic tests (DCISionRT and AidaBreast) to healthcare providers and patients. Revenue is generated through test fees billed to insurance payers and patients. The company accepts all insurance plans and offers financial assistance programs.
  2. Test Commercialization: Commercialization of diagnostic tests for early-stage breast cancer. Projected revenue of $40M for current year following FDA breakthrough device designation for AidaBREAST test.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goInsurance and self-pay options available

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Prelude product offering

Product offering

Core offering

PreludeDx operates a CLIA-certified molecular diagnostics laboratory that provides proprietary genomic and multi-omic biosignature tests for early-stage breast cancer. Its core products—DCISionRT for ductal carcinoma in situ (DCIS) and AidaBreast for early-stage invasive breast cancer—use AI-integrated biomarker analysis of patient tissue samples to generate Decision Scores that predict 10-year recurrence risk and identify which patients will benefit from radiation therapy. Tests are physician-ordered and results are returned within 3-5 days to support personalized treatment planning.

Product overview

PreludeDx (Prelude Corporation) is a molecular diagnostics company specializing in precision medicine for early-stage breast cancer. The company's portfolio consists of two core genomic tests: DCISionRT (launched 2017) for ductal carcinoma in situ (DCIS) patients, and AidaBreast (in development) for early-stage invasive breast cancer patients. Both tests use proprietary multi-omic biosignatures combined with AI algorithms to generate Decision Scores predicting recurrence risk and radiation therapy benefit. DCISionRT is a 7-gene biosignature while AidaBreast integrates spatial biology with multiplex protein expression and targeted RNA sequencing. The company also offers a web-based ordering portal and a second opinion service (Breast SOS).

Differentiator

Problem solved

Functional benefit

Brands

  • DCISionRT: Genomic test for ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit and recurrence risk
  • AidaBreast
  • Breast SOS

Products and services

  • DCISionRT A 7-gene genomic biosignature test for ductal carcinoma in situ (DCIS) that predicts 10-year recurrence risk and identifies which patients will benefit from radiation therapy following breast-conserving surgery. The test generates a Decision Score (0-10) and classifies patients as Low Risk, Elevated Risk, or Residual Risk. It is intended for breast cancer physicians (surgeons, radiation oncologists) treating DCIS patients and results are returned within 3-5 days.
  • AidaBreast A multi-omic diagnostic assay for early-stage invasive breast cancer that integrates spatial biology (multiplex immunofluorescence), targeted RNA sequencing, and AI to predict 10-year locoregional recurrence risk and radiation therapy benefit for women following breast-conserving surgery. Targets HR+/HER2-negative early-stage invasive breast cancer patients (T1-T2, node-negative) and generates a Decision Score and Radio Resistance Index (RRI).
  • Breast SOS (Second Opinion Service) A second opinion service offering for patients seeking additional consultation on DCIS diagnosis and treatment decisions, supporting personalized treatment planning through expert clinical review.

Quantifiable outcome

  • DCISionRT testing changed radiation therapy recommendation in 38% of patients (n=770, p<0.0001) in PREDICT study of 2,007 patients
  • +4 more outcomes

Companies that use Prelude

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Prelude technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Prelude partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered strategic and core.

  • QuanterixstrategicTechnology or Integration · 17 April 2026Quanterix and PreludeDx co-developed and validated AidaBREAST, a multi-omic assay that predicts locoregional recurrence risk and radiation therapy benefit. Quanterix's Simoa/spatial proteomics technology was integrated with RNA sequencing and AI for the assay. The assay was validated with 922 patients across US and Sweden.
  • GenesisCarecoreChannel Partner/ Reseller/ DistributorGenesisCare partnership provides global access to DCISionRT for patients, particularly through radiation oncology centers in Australia and internationally. Enables PreludeDx to expand geographically through GenesisCare's network of cancer treatment facilities.
  • Royal Melbourne HospitalstrategicStrategic or Co-development PartnerRoyal Melbourne Hospital in Australia conducted the first independent validation of AidaBreast test involving over 400 women with early-stage invasive breast cancer. The validation confirmed the test's prognostic and predictive capabilities for radiation therapy decision-making.
  • University of California San Francisco (UCSF)coreTechnology or IntegrationPreludeDx licensed biomarkers and technology from UCSF for development of DCISionRT and other breast cancer diagnostic tests. Both DCISionRT and AidaBreast tests were developed from biomarkers licensed from UCSF.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Prelude competitors and assessment

Company assessment

Direct peers

  • Exact Sciences: Acquired Genomic Health and Oncotype DX, the dominant 21-gene breast cancer recurrence test, making it the most direct competitor to DCISionRT in early-stage breast cancer risk stratification and treatment decision-making.
  • Agendia: Developer of MammaPrint (70-gene signature) and BluePrint for early-stage breast cancer recurrence and molecular subtyping; directly competes with DCISionRT and AidaBreast in guiding adjuvant and radiation therapy decisions.
  • NanoString Technologies: Markets Prosigna (PAM50) gene expression assay for breast cancer prognosis using the nCounter platform; offers an alternative genomic risk-stratification solution for postmenopausal early-stage breast cancer patients.
  • Biotheranostics (Hologic): Develops Breast Cancer Index (BCI), a gene expression test predicting recurrence risk and benefit of extended endocrine therapy in early-stage HR+ breast cancer; positioned similarly to AidaBreast.

Broad incumbents

  • Myriad Genetics: Established molecular diagnostics company offering EndoPredict for breast cancer recurrence risk as well as hereditary cancer tests (BRACAnalysis); competes across multiple precision oncology segments.
  • Veracyte: Genomic diagnostics company with a growing breast cancer franchise (e.g., Prosigna acquired via NanoString partnership) and broader oncology/urology test menu; competes for payer mindshare and physician adoption.
  • NeoGenomics: Specialized oncology reference laboratory offering comprehensive profiling and breast cancer assays; an alternative CLIA lab channel for hospitals ordering recurrence-risk testing.
  • Guardant Health: Liquid biopsy and precision oncology company expanding into MRD and therapy selection; adjacent competitor as blood-based alternatives emerge for early-stage breast cancer risk stratification.

Emerging players

  • Natera: Molecular diagnostics company expanding from cell-free DNA / MRD into oncology; a potential competitor for the multi-omic, AI-driven oncology testing market Prelude is targeting.
  • Caris Life Sciences: Offers multi-omic tumor profiling (MI Profile) combining WES/WTS, proteomics, and AI; competes for the same physician customers seeking AI-driven precision oncology decision support.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Prelude social profiles

Digital presence

Prelude compliance and trust

Trust signal

Compliance3 records

Prelude financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prelude leadership team

Management profile

Number of profiles

Profiles6 records

Prelude funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prelude M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prelude

What does Prelude do?

PreludeDx operates a CLIA-certified molecular diagnostics laboratory that provides proprietary genomic and multi-omic biosignature tests for early-stage breast cancer. Its core products—DCISionRT for ductal carcinoma in situ (DCIS) and AidaBreast for early-stage invasive breast cancer—use AI-integrated biomarker analysis of patient tissue samples to generate Decision Scores that predict 10-year recurrence risk and identify which patients will benefit from radiation therapy. Tests are physician-ordered and results are returned within 3-5 days to support personalized treatment planning.

Is Prelude a public or private company?

Prelude is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prelude founded?

Prelude was founded in 2009. It employs 51 to 100 people.

Where is Prelude based?

Prelude is headquartered in Laguna Hills, United States, in the North America region.

How does Prelude make money?

Two revenue lines are on record. Laboratory Diagnostic Testing Services are the primary driver. The others are test Commercialization.

Who are Prelude's main competitors?

Direct peers on record are Exact Sciences, Agendia, NanoString Technologies and Biotheranostics (Hologic). Broad incumbents are Myriad Genetics, Veracyte, NeoGenomics and Guardant Health. Emerging players are Natera and Caris Life Sciences.

Does Prelude have an API?

No public API is recorded for Prelude.

What industry is Prelude in?

Prelude's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization, with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePreludeDx Announces Collaboration with Learn Look Locate to Expand Patient Education Around DCIS Treatment DecisionsPreludeDx and Learn Look Locate announced a collaboration to launch a patient guide on DCIS treatment decisions. The guide covers recurrence risk, radiation therapy, and DCISionRT, a molecular test for personalized risk assessment. The resource aims to help patients ask informed questions with their physicians.OcbjPreludeDx Nears $40M with New Breast Cancer TestPreludeDx, a Laguna Hills-based medical diagnostics company, is on track to generate $40 million in revenue this year following FDA breakthrough device designation for its AidaBreast test, which assesses 10-year breast cancer recurrence risk and predicts radiation therapy benefit. The new test triples the company's addressable market beyond the roughly $500 million market for its existing DCISionRT test, supporting Prelude's mission to reduce overtreatment in early-stage breast cancer. The company has grown from five employees in 2009 to 100 employees today, with both tests developed from biomarkers licensed from UCSF.Ledger InsightsApollo, Bpifrance, SBI part of $175m fundraise for DeFi lending protocol Morpho - Ledger Insights - blockchain for enterpriseMorpho Association raised $175 million in a round co-led by Paradigm, a16z crypto, and Ribbit Capital, with Apollo, Circle Ventures, and others participating. Apollo agreed to buy up to 90 million Morpho tokens over four years. The protocol has attracted roughly $11 billion in deposits, of which about $3.5 billion has been lent out.VestbeePrelude secures $20M to build the trust layer for the AI internetPrelude, a Paris-based SMS verification startup, raised $20 million in a Series A round led by 20VC. The funds will scale its trust infrastructure through telecom partnerships, expanded API coverage, and machine learning-based fraud detection. The company previously raised $8 million in 2024.MaddynessIA : deux anciens de Zenly lèvent 20 millions de dollars pour leur solution de vérification téléphonique anti-fraudePrelude, founded by former Zenly executives, raised $20 million in a Series A led by 20VC. The anti-fraud verification platform aims to reduce verification costs by 40% and expand in the U.S., with plans to hire 30 more employees.PanewslabRWA周刊:CLARITY法案最早或于5月9日进行审议;美国证券清算巨头DTCC计划于7月启动代币化RWA试点交易RWA on-chain market value reached $30.91 billion, while stablecoin monthly transfers fell 25.68% to $8.16 trillion. The US Senate Banking Committee may vote on the CLARITY bill on May 9, and DTCC plans to launch tokenized RWA trading in July.AijournPreludeDx Receives FDA Breakthrough Device Designation for AidaBREAST® – Early-Stage Invasive Breast Cancer AssayPreludeDx announced that the U.S. Food and Drug Administration has granted Breakthrough Device designation for its AidaBREAST test, which provides individualized prognostic risk assessment and predicts radiation therapy benefit for women with early-stage invasive breast cancer. The test integrates multi-omic data with spatial biology technology to generate patient-specific assessments of 10-year locoregional recurrence risk following breast-conserving surgery. This marks PreludeDx's second FDA Breakthrough Device designation, following its DCISionRT test, and the priority review status may significantly accelerate the regulatory timeline for bringing the technology to patients.PR NewswirePreludeDx Receives FDA Breakthrough Device Designation for AidaBREAST® - Early-Stage Invasive Breast Cancer AssayThe U.S. Food and Drug Administration has granted Breakthrough Device designation for PreludeDx's AidaBREAST test, a multi-omic diagnostic assay for early-stage invasive breast cancer that predicts 10-year locoregional recurrence risk and radiation therapy benefit. This is PreludeDx's second FDA Breakthrough Device designation, following its DCISionRT test, enabling priority FDA review that can significantly accelerate the technology's path to market. The test integrates spatial biology, multiplex protein expression, and targeted RNA sequencing with artificial intelligence to generate patient-specific risk assessments following breast-conserving surgery.BioSpacePreludeDx Receives FDA Breakthrough Device Designation for AidaBREAST® - Early-Stage Invasive Breast Cancer AssayPreludeDx announced the FDA granted Breakthrough Device designation for its AidaBREAST test, which predicts radiation therapy benefit and 10-year locoregional recurrence risk for early-stage invasive breast cancer. The test is the only risk assessment for stage I,IIa breast cancer that predicts radiation benefit. The company expects to advance the test through the regulatory process.Stock TitanQuanterix powers breast cancer recurrence testPreludeDx and Quanterix Corporation announced AidaBREAST, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, developed on Quanterix's PhenoImager HT platform. The validation study included 922 hormone receptor-positive, HER2-negative patients across four academic and clinical centers in the United States and Sweden with a median follow-up of approximately 10 years. The test integrates spatial multiplex protein expression with targeted next-generation RNA sequencing to provide personalized risk assessment and treatment guidance for early-stage breast cancer patients.